Obesity: Definition, Health Risks, Causes, and Evidence-Based Management

Obesity is a chronic, relapsing, multifactorial disease defined by excessive adiposity impairing health—not merely high BMI. However, BMI ≥30 kg/m² remains the clinical screening threshold.

Classification (BMI)

  • Overweight: 25–29.9
  • Class I Obesity: 30–34.9
  • Class II: 35–39.9
  • Class III (Severe): ≥40

Limitations: Doesn’t distinguish fat vs. muscle, visceral vs. subcutaneous. Waist circumference (>102 cm M, >88 cm F) and body composition add precision.

Major Health Consequences

  • Cardiometabolic: T2DM, hypertension, dyslipidemia, ASCVD, HFpEF, stroke.
  • Cancer: 13 obesity-linked cancers (endometrial, esophageal, colorectal, breast postmenopausal, renal, hepatic, etc.).
  • Mechanical: Osteoarthritis, obstructive sleep apnea, GERD, incontinence.
  • Metabolic: NAFLD/NASH, insulin resistance, PCOS, infertility.
  • Psychosocial: Depression, anxiety, weight stigma, reduced quality of life.
  • COVID-19: Independent risk factor for severe outcomes.

Etiology: It’s Not Just "Calories In/Out"

  • Genetics: 40–70% heritability (polygenic; FTO, MC4R, etc.).
  • Environment: Ultra-processed food environment, sedentary design, food marketing, stress, sleep deprivation, endocrine disruptors.
  • Physiology: Hormonal dysregulation (leptin resistance, ghrelin, GLP-1, PYY, insulin) defends higher set point.
  • Medications: Glucocorticoids, antipsychotics, antidepressants, insulin, β-blockers.
  • Developmental: Epigenetic programming (maternal obesity, gestational diabetes).

Evidence-Based Treatment Pyramid

  1. Lifestyle (Foundation): Medical nutrition therapy (500–750 kcal deficit, high protein, fiber, whole foods), 150–300 min/week moderate activity + resistance, behavioral therapy (CBT, self-monitoring, stimulus control), sleep hygiene, stress management.
  2. Pharmacotherapy (BMI ≥30 or ≥27 + comorbidity): GLP-1 RAs (semaglutide, liraglutide), GIP/GLP-1 (tirzepatide), phentermine/topiramate, bupropion/naltrexone, orlistat. Average loss: 5–20%.
  3. Metabolic/Bariatric Surgery (BMI ≥40 or ≥35 + comorbidity): Sleeve gastrectomy, RYGB, SADI-S. Durable 25–35% total body weight loss; remission of T2DM, HTN, OSA.

Stigma Is a Barrier

Weight bias in healthcare delays care, reduces adherence, worsens outcomes. Person-first language ("person with obesity"), shared decision-making, and treating obesity as a chronic disease—not a moral failing—are essential.

Obesity is treatable. The tools exist. Access, empathy, and long-term support are the gaps.

Infertility - Related Articles